Skip to content
Screener

Stoke Therapeutics, Inc. STOK Investing Cash Flow

Investing Cash Flow at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$23.5M+120%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$123.1M+173%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$331.24M-503%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-$344.28M-574%
CalAmp logo
CalAmpCAMP
$0+100%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
-$183.65M-7,875%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.06B+187%
Enterprise value$1.91B+206%
P/S64.2×+60.6×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211874
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Purchases of marketable securities(9,853)(19,016)
Purchases of property and equipment(353)(152)
Proceeds from maturity of marketable securities60,90032,800
Net cash used in investing activities50,69413,632
Cash flows from financing activities:
Proceeds from Employee Stock Purchase Plan465370
Proceeds from issuance of common stock upon exercise of stock options3,2051,004
Proceeds from issuance of common stock in controlled equity offering sales agreements80,657

Item 1. Financial Statements.

FAQ

What is Stoke Therapeutics, Inc.'s investing cash flow?
Stoke Therapeutics, Inc. (STOK) reported investing cash flow of $50.69M in Q1 2026.
How has Stoke Therapeutics, Inc.'s investing cash flow changed year-over-year?
Stoke Therapeutics, Inc.'s investing cash flow increased by 271.9% year-over-year, from $13.63M to $50.69M.
What is the long-term trend for Stoke Therapeutics, Inc.'s investing cash flow?
Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s investing cash flow has grown at a 36.0% compound annual growth rate (CAGR), from $105.95M to -$195.91M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Stoke Therapeutics, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude